GENFIT: First Half-Year 2020 Financial Report and New Corporate Strategy
Cash position of €226 million at June 30, 2020 (€277 million at December 31, 2019) New Corporate strategy focused on two priority areas: Development of elafibranor in Primary Biliary Cholangitis (PBC): ongoing enrolment for Phase 3 clinical trial ELATIVE™ …